(Państwowa Szkoła Wyższa im. Papieża Jana Pawła II w Białej Podlaskiej, 2019-01-14)
Meretskyi, Viktor; Meretska, Iryna; Pertsovych, Vasyl
Venous thromboembolism is the third most common cause of vascular death after myocardial
infarction and stroke, and is associated with considerable morbidity and premature mortality.
The incidence of the most serious consequence of venous thromboembolism, fatal pulmonary
embolism, ranges from 0.01% to 5% among hospitalised medical patients with multiple
risk factors, and is currently considered the commonest avoidable cause of hospital death.
Rivaroxaban is a small-molecule factor Xa inhibitor that belongs to a new class of direct
oral anticoagulant agents that directly inhibit single enzymes in the coagulation pathway.
Rivaroxaban has many advantages over vitamin K antagonists and unfractionated heparin
and may become an alternative to traditional anticoagulant agents in patients at risk for
thromboembolism. Moreover, antidotes exist and are in the progress of development, both
specific and non-specific, for the treatment of overdose or side effects, including bleeding.